Idenix Pharmaceuticals (IDIX) Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Tweet Send to a Friend
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced that it has initiated a proof-of-concept study of IDX184, a liver-targeted nucleotide prodrug candidate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
